VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
Rhea-AI Summary
VivoSim (Nasdaq: VIVS) presented new data on its AI-enabled NAMkind Liver and NAMkind GI platforms at ESTIV 2026. In a 92-compound clinical liver dataset, NAMkind Liver showed 91% accuracy, 90% sensitivity, 95% specificity, 99% precision, and >90% sensitivity versus 50–65% for traditional methods.
The models produced <5% liver-toxicity false positives versus >10% for some current approaches and were used to characterize toxicity for small molecules, TKIs and antibody-drug conjugates, including Trastuzumab Emtansine and Trastuzumab Deruxtecan.
Positive
- NAMkind Liver accuracy 91% on 92-compound clinical dataset
- 90% sensitivity, 95% specificity, 99% precision in repeat-dose liver model
- >90% liver-tox sensitivity versus traditional methods at 50–65%
- <5% liver-tox false positives compared with >10% for some current methods
- Validated across modalities including small molecules, TKIs and ADCs
Negative
- None.
News Market Reaction – VIVS
In the Jun 29 session, VIVS gained 2.91%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.1% during that session. Argus tracked a trough of -13.3% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 7.6x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | AI GI toxicity update | Positive | -0.7% | Announced AI model predicting drug‑induced diarrhea using NAMkind intestinal data. |
| Apr 01 | Public offering pricing | Negative | +13.3% | Priced up to $4M best‑efforts equity offering with attached common warrants. |
| Mar 24 | ADC toxicity data | Positive | -2.4% | Released data validating NAMkind liver and intestine models for ADC toxicity prediction. |
| Mar 03 | Sales leadership hire | Positive | -12.7% | Appointed VP of Global Sales to drive commercial expansion of NAM services. |
| Feb 11 | ADC data preview | Positive | +0.0% | Planned debut of ADC validation data for NAMkind liver and intestine at SOT meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VIVS news, often scientifically positive or strategic, has mostly coincided with flat-to-negative price reactions, with a notable divergence rally on an otherwise dilutive offering.
Key Terms
antibody drug conjugates (adcs) medical
tyrosine kinase inhibitor (tki) medical
preclinical safety medical
histological medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)
SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced that data demonstrating the power of its advanced 3D human tissue models will be featured in two presentations at the European Society of Toxicology’s annual conference.
The presentations collectively showcase the best-in-industry predictive power of VivoSim's proprietary AI-enabled NAMkind™ Liver and NAMkind™ GI platforms. In liver toxicology testing, across a set of compounds where animal models and traditional methods provide 50
These powerful results help VivoSim clients avoid expensive mistakes in drug development, at a time when the industry is undergoing a shift in preclinical safety evaluation. "With a heavy push from the US FDA, the pharmaceutical industry is moving away from traditional animal testing toward high-fidelity, human-relevant alternatives," said Keith Murphy, VivoSim Executive Chairman. "As our newest data show, using AI-informed models in highly accurate tissues, we detect the problems that pharma typically misses. When a pharma has a miss, the cost to them is many lost years and
The United States Food and Drug Administration (FDA) is actively encouraging human-relevant NAMs in place of animal studies, a push that is resulting in greater pharma demand for new technologies. After presenting its April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies, the FDA recently reported that it is meeting its goals for stimulating pharma uptake of these new models. VivoSim’s novel models offer perhaps the most predictive tool to make FDA’s vision a reality.
VivoSim’s superior results are achieved by a combination of the best biological model with the most representative primary human cell types, leveraging multiple endpoints as readouts for best prediction, and training AI prediction models with multiple endpoints that provide a rich data set, yielding high prediction accuracy. In addition to testing traditional oral pill small molecules, VivoSim is establishing competitive advantages across new biotech modalities such as antibodies, siRNA, and gene therapies. Adding to the data supporting its industry leadership in small molecules as outlined above, the company has done extensive testing of Antibody Drug Conjugates (ADCs), one of oncology’s fastest-growing modalities, with comparable accuracy results in terms of predicting the clinical profiles of ADCs for liver toxicity and diarrhea. Globally, hundreds of ADC candidates are now in active clinical development against over 50 molecular targets — 41 of them already in Phase III — and the pipeline remains overwhelmingly oncology-focused, led by HER2- and TROP2-directed programs in breast and lung cancer. Therapies still fail in human trials, most often on safety or efficacy. VivoSim’s mission is to close gaps in the ability to predict outcomes before a drug enters expensive clinical trials.
“These results show our human-relevant models let developers move from detecting liabilities to predicting risk,” said Amar Sethi, MD, PhD, Chief Scientific Officer of VivoSim. “Whether we are unraveling the cause of TKI-induced diarrhea or guiding the design of safer, more effective ADC linker-payload combinations, our multi-endpoint profiling gives teams the translational signatures they need to retire toxic liabilities long before a single patient is dosed.”
Overall, the findings show that the Company’s human-relevant models can predict liver and gastrointestinal toxicity — for both traditional small molecules and complex antibody-drug conjugates (ADCs) — with accuracy that tracks real clinical outcomes. The data are being presented at The 23rd International Congress of the European Society of Toxicology In Vitro (ESTIV 2026) in Maastricht, the Netherlands, which takes place from June 29 to July 2, 2026.
Key highlights of the presented data demonstrating VivoSim’s ability to achieve definitive translational signatures across complex organ systems:
- High-Accuracy Liver Profiling: Benchmarked against a clinical small-molecule dataset of 92 compounds, the NAMkind™ Liver spheroid model achieved a predictive accuracy of
91% , with90% sensitivity,95% specificity, and99% precision under repeat-dose conditions. The multi-endpoint profiling suite effectively minimized false negatives and successfully resolved intra-class toxicities, such as within thiazolidinediones (TZDs). - Mechanistic GI Insights: Using the multicellular human intestinal barrier model (NAMkind™ GI), VivoSim successfully integrated multiple endpoints including barrier function to resolve distinct mechanistic classes of tyrosine kinase inhibitor (TKI)-induced diarrhea.
Deconvolution of ADC Toxicity: Critically, both platforms demonstrated a unique capacity to evaluate advanced modalities by differentiating ADC risk based on structural properties. The GI model established that Trastuzumab-deruxtecan-mediated injury is exposure-dependent and payload-driven through detailed histological tracking. Meanwhile, the Liver model successfully differentiated hepatic risk based on linker stability and payload permeability when comparing Trastuzumab Emtansine and Trastuzumab Deruxtecan.
About VivoSim Labs
VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding NAMKind™, including target turnaround time and its potential to help users de-risk their pipelines, avoid costly downstream failures, reduce rework, prioritize the right assets, move faster, save millions and reduce risk; VivoSim’s commercial presence across Asia-Pacific; the evaluation and acceptance of scientifically robust NAM-based evidence; the Company’s ability to capture growing demand in the in vitro toxicology testing market; demand for human-relevant toxicology; the market opportunity and market size of gastrointestinal in vitro models and toxicology services; and the Company’s scaling capacity to support expanding global demand and development needs. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 11, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.
